What happened with CTMX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
CytomX Therapeutics is a clinical-stage drug developer seeking to treat cancer while limiting harm to healthy tissue. Its PROBODY platform puts a removable peptide mask over a drug’s target-binding site. Enzymes found in tumors are intended to remove that mask, allowing the drug to bind its target. This remains an investigational approach; its own candidates include Varseta-M and CX-801, both in early clinical development.
Drug companies pay CytomX for access to its technology and for research work. Almost all revenue has come from these collaborations through license payments, research-cost reimbursements and payments for reaching agreed development milestones. Agreements such as its Regeneron partnership also provide for royalties if resulting drugs reach the market. Bristol Myers Squibb has supplied most revenue, but CytomX has completed its assigned work under that collaboration, leaving the partner responsible for further research and development of the ongoing programs.
CytomX has no approved products and has never earned product-sales revenue. It cannot commercialize its candidates before regulatory approval. Collaboration income depends on partners continuing programs and on development progress; the company also uses share sales to finance operations and needs additional capital to continue development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
CytomX depends on clinical progress and partner funding, including Astellas, a significant collaboration-revenue source that chose not to advance its remaining preclinical programs in early 2026.
Janux Therapeutics competes with CytomX to develop immunotherapies that activate conditionally, including drugs that bring T cells to solid tumors while aiming to limit toxicity. Watch efficacy and safety in its Phase 1 JANX007 prostate-cancer and JANX008 solid-tumor trials; Janux has no product-sales revenue yet.
Xilio Therapeutics competes with CytomX on drugs that mask immune-stimulating proteins and T-cell engagers until they activate inside tumors, aiming to limit healthy-tissue toxicity. Its masked IL-12, efarindodekin alfa, is in a Phase 2 trial for advanced solid tumors, making its efficacy and safety data a concrete test of this approach.
CytomX's potential milestones and sales royalties now depend on Bristol Myers Squibb advancing the ongoing programs it licenses using CytomX's PROBODY technology. Bristol Myers Squibb took responsibility for further research and development after CytomX completed its obligations in the second quarter of 2025, so progress in those programs matters more than the earlier research revenue.
CytomX pays AbbVie for rights to the cancer-killing component in Varseta-M, a TOP1-inhibitor payload, while AbbVie also develops competing cancer treatments, including colorectal-cancer therapies. Watch both Varseta-M's progress, which can trigger payments to AbbVie, and AbbVie's colorectal-cancer results.
Regeneron pays for both companies' partnered oncology research and subsequent development, giving CytomX funding plus potential milestones and sales royalties for its licensed technology. Watch whether Regeneron expands the programs: work narrowed mainly to the lead preclinical program in 2025, reducing CytomX's revenue from the partnership.
BioAtla competes directly for CytomX's Varseta-M opportunity with a drug that brings T cells to cancers bearing the same EpCAM target. BioAtla also develops antibodies intended to bind in acidic tumors rather than normal tissue; its EpCAM trial results are the closest comparison to watch.
Werewolf Therapeutics competes with CytomX on immune-stimulating proteins designed to remain inactive until tumor enzymes release them—the cytokine-prodrug approach. Its conditionally activated IFNα drug JZP898 is licensed to Jazz for development and commercialization, making that program's progress a test of tumor-focused immune stimulation.
Adagene competes with CytomX's PROBODY platform through antibody-masking cancer therapies and with Varseta-M through colorectal-cancer programs. Its lead antibody candidate ADG126 and colorectal-cancer trial news are worth watching for how competing immunotherapies could affect Varseta-M's eventual adoption.
Vir Biotechnology competes with CytomX on masked drugs that bring T cells to solid tumors; its dual-masked VIR-5500 targets PSMA in prostate cancer. Watch VIR-5500's progress and the closing of its February 2026 Astellas agreement, under which the companies plan to share development costs and, if approved, U.S. profits and losses.
Xencor competes with CytomX on engineered drugs that activate immunity against solid tumors, including T-cell engagers and cytokines. Xencor earns upfront payments, milestones and royalties by licensing drug rights to partners, while its solid-tumor trial results offer a comparison for CytomX's efficacy and safety.
CytomX funds CX-908's development using technology licensed from Amgen and may owe Amgen milestones and sales royalties, while Amgen also develops competing T-cell engagers. Amgen's May 2025 termination of a separate EGFR product license led CytomX to recognize all remaining deferred revenue under that agreement, rather than signaling new research funding.
Context Therapeutics competes with CytomX on drugs that connect T cells to solid tumors through CD3, so tumor targeting and healthy-tissue toxicity matter to both. Watch its Phase 1 CTIM-76 trial for evidence of distinguishing tumor-associated CLDN6 from related proteins on healthy tissue; Context has not yet generated revenue.
Moderna's research budget directly affects CytomX's revenue because it licenses PROBODY technology for mRNA-based therapies and paused the partnered programs for budget reasons. Watch whether Moderna funds a restart: CytomX's revenue from Moderna fell from $16.881 million in 2024 to $0.031 million in 2025.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb is responsible for advancing the ongoing oncology programs using CytomX's PROBODY technology, so its report can indicate whether those programs still offer CytomX a path to potential milestones and royalties.
Look for updates on the two remaining preclinical programs. If Bristol Myers Squibb advances them, CytomX retains a route to potential milestone payments and eventual sales royalties; if the programs are paused or stopped, that future revenue opportunity weakens, and CytomX cannot set the pace because Bristol Myers Squibb is responsible for further development. The takeaway is whether this collaboration still has a path to future income for CytomX.
CytomX Therapeutics, Inc. earningsThis company
CytomX has no product-sale revenue and relies on collaborations to fund research, so this report will show whether Varseta-M and CX-801 are advancing at a pace its resources can support.
Read updates on Varseta-M and CX-801 alongside collaboration revenue and cash used in operations: collaboration revenue comes from licenses and research services, not product sales, and does not necessarily equal cash received in the same period. If the programs advance while collaboration revenue holds up and cash use stays contained, CytomX is turning limited resources into pipeline progress; if they stall as revenue falls and cash keeps going out, the company may need new financing or cuts. The conclusion is whether its available resources can keep its own programs moving.
Moderna, Inc. earningsMRNA
Moderna's research budget will help show whether its paused PROBODY programs might restart, reopening a source of paid research work for CytomX.
Watch for whether Moderna restores budget and restarts the paused programs; CytomX's revenue from Moderna fell from $16.881 million in 2024 to $0.031 million in 2025. A restart that leads to research work would give CytomX a chance to recognize collaboration revenue again; if the programs remain paused, that source is likely to stay negligible. The conclusion is whether Moderna's budget is again supporting work that can generate revenue for CytomX.
BioAtla, Inc. earningsBCAB
BioAtla is testing an EpCAM-targeted T-cell therapy for the same cancer target as CytomX's Varseta-M, making its trial results a close comparison for that treatment opportunity.
Look for signs of tumor activity in BioAtla's EpCAM program and whether toxicity limits treatment; results from separate trials are not a direct head-to-head comparison. Meaningful activity with manageable toxicity would make BioAtla a credible rival for the same patient opportunity and raise the bar for CytomX to establish Varseta-M's benefit and safety. Weak activity or limiting toxicity would ease that specific pressure, but would not prove Varseta-M works. The takeaway is how strong a competitor BioAtla may be for CytomX's EpCAM opportunity.
